Literature DB >> 8880390

Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.

E J Estlin1, S Ablett, D R Newell, I J Lewis, L Lashford, A D Pearson.   

Abstract

The current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of current and recently published United Kingdom Childrens Cancer Study Group Phase I trials, and a discussion of some of the difficulties faced in the methodology and evaluation of Phase I studies in children.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8880390     DOI： 10.1007/bf00173679

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  22 in total

1.  The conduct of phase I-II clinical trials in children with cancer.

Authors:  C B Pratt
Journal:  Med Pediatr Oncol       Date:  1991

2.  [Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood].

Authors:  R Erttmann; U Bode; N Erb; P Forcadell de Dios; P Gutjahr; R Haas; N Kuhn; H Siewert; G Landbeck
Journal:  Klin Padiatr       Date:  1988 May-Jun       Impact factor: 1.349

3.  A comparison of two phase I trial designs.

Authors:  E L Korn; D Midthune; T T Chen; L V Rubinstein; M C Christian; R M Simon
Journal:  Stat Med       Date:  1994-09-30       Impact factor: 2.373

Review 4.  Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs.

Authors:  W E Evans; J H Rodman; M V Relling; W R Crom; G K Rivera; C B Pratt; W M Crist
Journal:  Med Pediatr Oncol       Date:  1991

5.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Authors:  M L Slevin; P I Clark; S P Joel; S Malik; R J Osborne; W M Gregory; D G Lowe; R H Reznek; P F Wrigley
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

6.  Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.

Authors:  J S Lee; R A Newman; S M Lippman; M H Huber; T Minor; M N Raber; I H Krakoff; W K Hong
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

7.  Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.

Authors:  L S Lashford; I J Lewis; S L Fielding; M A Flower; S Meller; J T Kemshead; D Ackery
Journal:  J Clin Oncol       Date:  1992-12       Impact factor: 44.544

8.  Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

Authors:  N M Marina; J Rodman; S J Shema; L C Bowman; E Douglass; W Furman; V M Santana; M Hudson; J Wilimas; W Meyer
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

9.  Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.

Authors:  S Negrier; J Michon; D Floret; E Bouffet; J C Gentet; I Philip; P Cochat; D Stamm; J Costil; M Gaspard
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

10.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

Authors:  P J Houghton; P J Cheshire; J C Hallman; M C Bissery; A Mathieu-Boué; J A Houghton
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.